Diamyd Medical To Pursue Accelerated Approval Pathway In US

Diamyd Medical To Pursue Accelerated Approval Pathway In US

By, Admin 11 September 2024

Diamyd Medical to pursue accelerated approval pathway in US for type 1 diabetes precision medicine

Overview

Diamyd Medical will pursue an accelerated approval pathway in the US for its antigen-specific immunotherapy, Diamyd (rhGAD65/alum), aimed at preserving endogenous insulin production in patients with stage 3 type 1 diabetes. An earlier interim study readout from the ongoing phase 3 trial, DIAGNODE-3, is planned to serve as the basis for a Biologics License Application (BLA) under the accelerated approval pathway. Results from the interim readout are expected around March 2026.

Words from CEO: Diamyd Medical

  • We are committed to working at full speed with our partners and in close dialogue with the FDA to seize this unprecedented opportunity of making Diamyd available to patients as quickly as possible,” says Ulf Hannelius, CEO of Diamyd Medical. 
  • The earlier readout from the DIAGNODE-3 trial represents a critical step in this process and our confidence in Diamyd’s disease-modifying benefits is boosted by the positive outcome of the recently announced futility analysis.  We look forward to working closely with the FDA to ensure that all necessary regulatory requirements are met.

Diamyd Medical for FTA

  • Diamyd Medical recently announced Fast track designation in the US for Diamyd, and that the US Food and Drug Administration (FDA) has acknowledged that accelerated approval could be sought based on a demonstration of significant treatment-related benefits on C-peptide levels, a measure of endogenous insulin production, in response to Diamyd administration. 
  • The FDA’s Accelerated approval programme allows drugs for serious conditions that fills an unmet medical need to be approved based on a surrogate endpoint. 
  • Using a surrogate endpoint allows the FDA the potential to approve these drugs faster.

DIAGNODE-3 Trial

  • To prepare the BLA under the FDA's Accelerated Approval Programme, Diamyd Medical plans to conduct an interim study readout, including efficacy data from approximately 170 participants who have completed their 15-month assessment and safety data from additional individuals enrolled in the DIAGNODE-3 trial. 
  • The primary endpoint for this analysis will be C-peptide, a surrogate endpoint now recognized by the FDA as reasonably likely to predict clinical benefit. 
  • Following the interim readout, the DIAGNODE-3 trial will continue to follow all enrolled patients until the 24-month end-of-study assessment. 
  • To date, 148 patients have been randomized in DIAGNODE-3. 
  • The results of the interim study readout are expected around March 2026, the exact time depending on the final number of participants to be included in the readout, followed by submission of a BLA under the accelerated approval pathway
  • The DIAGNODE-3 trial, which is being conducted in eight European countries and the United States, is expected to fully recruit approximately 330 patients by the end of 2025, and all patients are expected to be fully treated before the time the earlier readout is to be performed. 
  • The trial focuses on recently diagnosed patients with stage 3 type 1 diabetes carrying the HLA DR3-DQ2 genotype; a subgroup of approximately 40% of stage 3 type 1 diabetes patients that has been shown to respond to Diamyd in previous trials.

Diamyd Medical for Prevention of Type 1 Diabetes

  • Diamyd Medical develops precision medicine therapies for the prevention and treatment of type 1 diabetes and LADA (latent autoimmune diabetes in adults). 
  • Diamyd is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the US as well as Fast Track Designation by the US FDA for the treatment of stage 1, 2 and 3 type 1 diabetes.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!